Steven Feldman to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Steven Feldman has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.934
-
Ramachandran V, Bertus B, Bashyam AM, Feldman SR. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. Ann Pharmacother. 2020 09; 54(9):872-878.
Score: 0.178
-
Kolli SS, Gabros SD, Pona A, Cline A, Feldman SR. Tildrakizumab: A Review of Phase II and III Clinical Trials. Ann Pharmacother. 2019 04; 53(4):413-418.
Score: 0.162
-
Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul; 24(7):617-622.
Score: 0.158
-
Feldman SR, Foster SA, Zhu B, Burge R, Al Sawah S, Goldblum OM. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis. J Drugs Dermatol. 2017 12 01; 16(12):1246-1252.
Score: 0.152
-
Howell ST, Cardwell LA, Feldman SR. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. Ann Pharmacother. 2018 04; 52(4):380-387.
Score: 0.152
-
Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011 Sep; 12(13):2041-54.
Score: 0.098
-
Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016 May; 74(5):841-50.
Score: 0.034